NCT06348108View on ClinicalTrials.gov

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

PHASE1RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 28, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2029

Conditions
Multiple MyelomaRefractory Multiple MyelomaRelapsed Multiple Myeloma
Interventions
BIOLOGICAL

Talquetamab

Given subcutaneously (SQ)

DRUG

Iberdomide

Given orally (PO)

DRUG

Dexamethasone

Given PO

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

Trial Locations (1)

94143

RECRUITING

University of Calfornia, San Francisco, San Francisco

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

collaborator

Celgene Corporation

INDUSTRY

lead

Thomas Martin, MD

OTHER